In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growth

Set Alert for Growth

Brand Spotlight: Novo Nordisk’s Semaglutide

Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease. 

Growth Launches

JCR Pharma: Crossing Oceans And The Blood-Brain Barrier

After 45 years as a domestic Japanese biopharmaceutical company, JCR Pharmaceuticals is expanding into global markets. The company is betting that its manufacturing strength – which helped land a COVID-19 vaccine manufacturing deal with AstraZeneca – and blood-brain barrier crossing J-Brain Cargo technology will lead to success in Western markets.   

Japan Business Strategies

Do It Yourself: Advantages Of Internal Gene Therapy Manufacturing

The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?

Manufacturing Gene Therapy

SERB And BTG SP – A Simple Jigsaw

The merging of the capabilities of Belgium’s SERB and the UK’s BTG Specialty Pharma could produce the world’s biggest antidotes manufacturer.

M & A BioPharmaceutical

Driving The Agenda For Next-Generation Pan-European Life Sciences Development

The COVID-19 pandemic has demonstrated the need for society to address health care challenges at speed – we ignore them at our peril. Equally, it has highlighted the power that can be deployed to develop new pharmaceuticals when the life sciences sector collaborates internationally to tackle a common cause.  

StartUps and SMEs Growth

When You Can’t Win For Losing: Kodak And The Reshoring Of US Pharmaceutical Manufacturing

Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.

Business Strategies Ingredients

Touchlight To Disrupt DNA Market With Synthetic Manufacturing

Touchlight has secured £42m ($60m) in funding to support efforts to triple its manufacturing capacity of synthetic DNA based on the company’s proprietary dbDNA platform – an enzyme made minimal linear DNA vector. The completed facility will have the capacity to produce 1kg of GMP DNA per month, enough for one billion COVID-19 vaccine doses.

Manufacturing Financing

The Value And Challenge Of Focus In Pharma

A 10-year review of the top 20 biopharmaceutical companies by revenue found that portfolio focus, not therapeutic area diversity, delivered the strongest growth rates.

Business Strategies Commercial

In Vivo’s Deals Of The Year 2020: Winners Revealed

For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Business Strategies Commercial

Are SPACs Good Or Bad For Biopharma?

Special Purpose Acquisition Companies (SPACs) homed in on the biopharma industry in 2020, providing biotech companies with a faster and looser route to the public market. Is there a downside?

Business Strategies Commercial

In Health Care You Don’t Become A Unicorn Overnight

The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.

Deals Medical Device

The Benefit In B Corps

Privately held Chiesi Farmaceutica, a global health care and biopharmaceuticals firm headquartered in Italy, became a certified B Corporation in 2019. The B Corp impact assessment framework helped Chiesi demonstrate its mission of becoming a “double purpose” business, one that executes on business objectives but also works to protect the environment and promote social justice. Will other companies follow suit?

Business Strategies Commercial
See All
UsernamePublicRestriction

Register